Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies

Diabetes

Volumn 60, Issue 11, 2011, Pages 2914-2921

  Serreze, David V ^a   Chapman, Harold D ^a   Niens, Marijke ^a   Dunn, Robert ^b   Kehry, Marilyn R ^b   Driver, John P ^a   Haller, Michael ^c   Wasserfall, Clive ^d   Atkinson, Mark A ^d  

^a JACKSON LABORATORY   (United States)

^b BIOGEN   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIBODY; IMMUNOGLOBULIN G2A; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AUTOANTIBODIES; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; PLASMA CELLS; PREDIABETIC STATE;

EID: 80755168884     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0705     Document Type: Article

References (44)

1. Silveira PA, Serreze DV, Grey ST. Invasion of the killer B's in type 1 diabetes. Front Biosci 2007;12:2183-2193
2. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 1998;161:1163- 1168
3. g7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet b cells of nonobese diabetic mice. J Immunol 1999; 163:743-750
4. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cellmediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998;161:3912-3918 (Pubitemid 28468965)
5. Hulbert C, Riseili B, Rojas M, Thomas JW. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J Immunol 2001;167: 5535-5538 (Pubitemid 33062740)
6. Silveira PA, Johnson EA, Chapman HD, Bui T, Tisch RM, Serreze DV. The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 2002;32:3657-3666 (Pubitemid 36024402)
7. Silveira PA, Dombrowsky J, Johnson E, Chapman HD, Nemazee D, Serreze DV. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol 2004;172:5086-5094 (Pubitemid 38456437)
8. Silveira PA, Chapman HD, Stolp J, et al. Genes within the Idd5 and Idd9/11 diabetes susceptibility loci affect the pathogenic activity of B cells in nonobese diabetic mice. J Immunol 2006;177:7033-7041 (Pubitemid 44715070)
9. Zekavat G, Rostami SY, Badkerhanian A, et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 2008;181:8133-8144
10. Greeley SA, Katsumata M, Yu L, et al. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 2002;8:399-402 (Pubitemid 34407036)
11. Inoue Y, Kaifu T, Sugahara-Tobinai A, Nakamura A, Miyazaki J, Takai T. Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. J Immunol 2007;179:764-774
12. Kendall PL, Yu G, Woodward EJ, Thomas JW. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J Immunol 2007;178:5643-5651 (Pubitemid 46674360)
13. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997;46:941-946 (Pubitemid 27220992)
14. Serreze DV, Chapman HD, Varnum DS, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med 1996; 184:2049-2053 (Pubitemid 26404497)
15. Skyler JS. Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 2007;81:768-771 (Pubitemid 46625122)
16. TrialNet Study Group. Further research to prevent and treat type 1 diabetes. Diabetes Forecast 2004;57:77-79
17. Fiorina P, Vergani A, Dada S, et al. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 2008;57:3013-3024
18. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007;117:3857-3867 (Pubitemid 350224095)
19. Xiu Y, Wong CP, Bouaziz JD, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008;180:2863-2875
20. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10:236-247
21. Pillai S, Cariappa A, Moran ST. Marginal zone B cells. Annu Rev Immunol 2005;23:161-196 (Pubitemid 40563168)
22. Mariño E, Batten M, Groom J, et al. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 2008;57: 395-404
23. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361: 2143-2152
24. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what's next? Diabetes 2010;59:1561-1571
25. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes 2005;54(Suppl. 2):S52-S61 (Pubitemid 43343331)
26. Yu L, Eisenbarth GS. Humoral autoimmunity. In Immunology of Type 1 Diabetes. Eisenbarth GS, Ed. Georgetown, TX, Landes Biosciences Publishers, 2004, p. 247-267
27. Melanitou E, Devendra D, Liu E, Miao D, Eisenbarth GS. Early and quantal (by litter) expression of insulin autoantibodies in the nonobese diabetic mice predict early diabetes onset. J Immunol 2004;173:6603- 6610
28. Mariño E, Villanueva J, Walters S, Liuwantara D, Mackay F, Grey ST. CD4(+) CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes 2009;58:1568-1577
29. Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci USA 1992;89:3290-3294
30. Serreze DV, Leiter EH, Hanson MS, et al. Emv30null NOD-scid mice. An improved host for adoptive transfer of autoimmune diabetes and growth of human lymphohematopoietic cells. Diabetes 1995;44:1392-1398
31. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007; 179:3351-3361
32. Hamel K, Doodes P, Cao Y, et al. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol 2008; 180:4994-5003
33. Gerling IC, Serreze DV, Christianson SW, Leiter EH. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes 1992;41:1672-1676
34. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol 1988;140:3801-3807
35. Chen YG, Scheuplein F, Osborne MA, Tsaih SW, Chapman HD, Serreze DV. Idd9/11 genetic locus regulates diabetogenic activity of CD4 T-cells in nonobese diabetic (NOD) mice. Diabetes 2008;57:3273-3280
36. Stratmann T, Martin-Orozco N, Mallet-Designe V, et al. Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J Clin Invest 2003;112:902-914 (Pubitemid 38063748)
37. Bonifacio E, Atkinson MA, Eisenbarth GS, et al. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 2001;50:2451-2458
38. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008;180:361-371
39. Melli K, Friedman RS, Martin AE, et al. Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J Immunol 2009;182:2590-2600
40. Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. Science 2007;317:627-629 (Pubitemid 47229955)
41. Chen Y-G, Choisy-Rossi C-M, Holl TM, et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005;174:1196-1204
42. Ly D, Mi Q-S, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006;177:3695-3704 (Pubitemid 44359901)
43. Kared H, Masson A, Adle-Biassette H, Bach JF, Chatenoud L, Zavala F. Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+) CD25(+) regulatory T-cells. Diabetes 2005;54:78-84 (Pubitemid 40105097)
44. Parker MJ, Xue S, Alexander JJ, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009;58:2277-2284